GlassScriptPhysician profile
Lorraine Stevens
NPI 1740585272
$863.89
in general payments reported to CMS, 2019-2025
17 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $86.20 · 2023: $187 · 2024: $270 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759 · Entertainment: $18.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.21 |
| Entertainment | $18.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $197.68 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Boston Scientific Corporation | $196.56 | 2023-2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $73.47 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $57.17 | 2022 | |
| Novo Nordisk INC | $52.12 | 2024-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $43.90 | 2024-2025 | |
| Amgen INC. | $34.95 | 2024-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $34.04 | 2024 | Mounjaro, Trulicity, Zepbound |
| Exact Sciences Corporation | $27.52 | 2023-2025 | Cologuard Collection Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.50 | 2025 | Lifevest |
| Astellas Pharma US INC | $20.41 | 2024 | Veozah |
| Pfizer INC. | $19.83 | 2025 | |
| Optos, INC. | $18.48 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Recordati_rare_diseases_inc. | $17.76 | 2024 | Signifor Lar, Isturisa |
| Bayer Healthcare Pharmaceuticals INC. | $16.33 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $16.04 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.13 | 2023 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorraine Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.